Direct compression tablet formulation of celecoxib enabled with a pharmaceutical solvate

Kunlin Wang; Changquan Calvin Sun

doi:10.1016/j.ijpharm.2021.120239

Direct compression tablet formulation of celecoxib enabled with a pharmaceutical solvate

Kunlin Wang, Changquan Calvin Sun

Pharmaceutics

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Celecoxib, an anti-inflammatory drug for pain and arthritis, is currently only available in capsule form. To reduce the onset time for a faster action and to lower the manufacturing cost, the tablet dosage form is more preferred. However, the commercial celecoxib (Form III) is not suitable for direct compression (DC) tablet manufacture due to poor flow, low bulk density, and tablet lamination. In this work, we overcome these challenges using a pharmaceutically acceptable dimethyl sulfoxide (DMSO) solvate of celecoxib. Aided with the DMSO solvate, an acceptable DC tablet formulation was successfully developed to manufacture tablets containing 200 mg celecoxib, with satisfactory manufacturability, disintegration, and in vitro dissolution performance.

Original language	English (US)
Article number	120239
Journal	International journal of pharmaceutics
Volume	596
DOIs	https://doi.org/10.1016/j.ijpharm.2021.120239
State	Published - Mar 1 2021

Bibliographical note

Funding Information:
Part of this work were carried out in the Characterization Facility, University of Minnesota, a member of the NSF-funded Materials Research Facilities Network (www.mrfn.org) via the MRSEC program. The Bruker-AXS D8 Venture diffractometer was purchased through a grant from NSF/MRI (#1229400) and the University of Minnesota.

Publisher Copyright:
© 2021 Elsevier B.V.

Keywords

Celecoxib
Crystal engineering
Direct compression
Formulation development
Solvate

PubMed: MeSH publication types

Journal Article

Access

10.1016/j.ijpharm.2021.120239

OpenUrl availability

Full text

Cite this

@article{88e3e6e02a804a2aa529e2c9e51b0c96,

title = "Direct compression tablet formulation of celecoxib enabled with a pharmaceutical solvate",

abstract = "Celecoxib, an anti-inflammatory drug for pain and arthritis, is currently only available in capsule form. To reduce the onset time for a faster action and to lower the manufacturing cost, the tablet dosage form is more preferred. However, the commercial celecoxib (Form III) is not suitable for direct compression (DC) tablet manufacture due to poor flow, low bulk density, and tablet lamination. In this work, we overcome these challenges using a pharmaceutically acceptable dimethyl sulfoxide (DMSO) solvate of celecoxib. Aided with the DMSO solvate, an acceptable DC tablet formulation was successfully developed to manufacture tablets containing 200 mg celecoxib, with satisfactory manufacturability, disintegration, and in vitro dissolution performance.",

keywords = "Celecoxib, Crystal engineering, Direct compression, Formulation development, Solvate",

author = "Kunlin Wang and Sun, {Changquan Calvin}",

note = "Funding Information: Part of this work were carried out in the Characterization Facility, University of Minnesota, a member of the NSF-funded Materials Research Facilities Network (www.mrfn.org) via the MRSEC program. The Bruker-AXS D8 Venture diffractometer was purchased through a grant from NSF/MRI (#1229400) and the University of Minnesota. Publisher Copyright: {\textcopyright} 2021 Elsevier B.V.",

year = "2021",

month = mar,

day = "1",

doi = "10.1016/j.ijpharm.2021.120239",

language = "English (US)",

volume = "596",

journal = "International journal of pharmaceutics",

issn = "0378-5173",

publisher = "Elsevier",

}

TY - JOUR

T1 - Direct compression tablet formulation of celecoxib enabled with a pharmaceutical solvate

AU - Wang, Kunlin

AU - Sun, Changquan Calvin

N1 - Funding Information: Part of this work were carried out in the Characterization Facility, University of Minnesota, a member of the NSF-funded Materials Research Facilities Network (www.mrfn.org) via the MRSEC program. The Bruker-AXS D8 Venture diffractometer was purchased through a grant from NSF/MRI (#1229400) and the University of Minnesota. Publisher Copyright: © 2021 Elsevier B.V.

PY - 2021/3/1

Y1 - 2021/3/1

N2 - Celecoxib, an anti-inflammatory drug for pain and arthritis, is currently only available in capsule form. To reduce the onset time for a faster action and to lower the manufacturing cost, the tablet dosage form is more preferred. However, the commercial celecoxib (Form III) is not suitable for direct compression (DC) tablet manufacture due to poor flow, low bulk density, and tablet lamination. In this work, we overcome these challenges using a pharmaceutically acceptable dimethyl sulfoxide (DMSO) solvate of celecoxib. Aided with the DMSO solvate, an acceptable DC tablet formulation was successfully developed to manufacture tablets containing 200 mg celecoxib, with satisfactory manufacturability, disintegration, and in vitro dissolution performance.

AB - Celecoxib, an anti-inflammatory drug for pain and arthritis, is currently only available in capsule form. To reduce the onset time for a faster action and to lower the manufacturing cost, the tablet dosage form is more preferred. However, the commercial celecoxib (Form III) is not suitable for direct compression (DC) tablet manufacture due to poor flow, low bulk density, and tablet lamination. In this work, we overcome these challenges using a pharmaceutically acceptable dimethyl sulfoxide (DMSO) solvate of celecoxib. Aided with the DMSO solvate, an acceptable DC tablet formulation was successfully developed to manufacture tablets containing 200 mg celecoxib, with satisfactory manufacturability, disintegration, and in vitro dissolution performance.

KW - Celecoxib

KW - Crystal engineering

KW - Direct compression

KW - Formulation development

KW - Solvate

UR - http://www.scopus.com/inward/record.url?scp=85100420584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100420584&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2021.120239

DO - 10.1016/j.ijpharm.2021.120239

M3 - Article

C2 - 33484921

AN - SCOPUS:85100420584

SN - 0378-5173

VL - 596

JO - International journal of pharmaceutics

JF - International journal of pharmaceutics

M1 - 120239

ER -

Direct compression tablet formulation of celecoxib enabled with a pharmaceutical solvate

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this